Advanced search
Publication Cover
Pain Management Volume 12, 2022 - Issue 2
Submit an article Journal homepage
3,361
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Lidocaine 700 mg Medicated Plaster for Postherpetic Neuralgia: Real-World Data from the German Pain E-Registry

Michael A Überall1 Institute of Neurological Sciences, Nürnberg, GermanyORCID Iconhttps://orcid.org/0000-0001-7165-9492View further author information
ORCID Icon,
Mariëlle Eerdekens2 Grünenthal GmbH, Aachen, GermanyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-6198-4806View further author information
ORCID Icon,
Els Hollanders2 Grünenthal GmbH, Aachen, GermanyView further author information
,
Irmgard Bösl2 Grünenthal GmbH, Aachen, GermanyView further author information
&
Ingo Sabatschus2 Grünenthal GmbH, Aachen, GermanyView further author information
Pages 195-209 | Received 16 Mar 2021, Accepted 20 Jul 2021, Published online: 10 Aug 2021

Figures & data

Figure 1. Data selection.
Figure 1. Data selection.

Table 1. Baseline characteristics before and after propensity score matching.

Table 2. Effectiveness assessment parameters at baseline and end of observation.

Table 3. Oral systemic recommended first-line medications documented for postherpetic neuralgia treatment in the oral systemic first-line medication group after switch from previous medication (n = 1711).

Figure 2. Changes in concomitant analgesic medications (taken by >60% of patients at baseline) over the observation period.

Strong opioids included morphine, hydromorphone, oxycodone ± naloxone, fentanyl, buprenorphine, tapentadol and others.

BL: Baseline; LMP: Lidocaine 700 mg medicated plaster; OSM: Oral systemic medication; W: Week.

Figure 2. Changes in concomitant analgesic medications (taken by >60% of patients at baseline) over the observation period.Strong opioids included morphine, hydromorphone, oxycodone ± naloxone, fentanyl, buprenorphine, tapentadol and others.BL: Baseline; LMP: Lidocaine 700 mg medicated plaster; OSM: Oral systemic medication; W: Week.
Figure 3. Change in pain intensity index, pain-related impairments and quality of life.

(A) Change from baseline over the observation period. Boxplots show median (middle horizontal line in the box), 25 and 75% quartiles (bottom and top lines of the box), and five and 95% percentiles (whiskers). Improvement is shown by reductions in pain intensity index and modified pain disability index, and by increases in quality of life impairment by pain. (B) Improvement versus baseline in pain intensity index at end of observation.

LMP: Lidocaine 700 mg medicated plaster; NRS: Numerical rating scale; OSM: Oral systemic medication; PIX: Pain intensity index; VAS: Visual analogue scale.

Figure 3. Change in pain intensity index, pain-related impairments and quality of life. (A) Change from baseline over the observation period. Boxplots show median (middle horizontal line in the box), 25 and 75% quartiles (bottom and top lines of the box), and five and 95% percentiles (whiskers). Improvement is shown by reductions in pain intensity index and modified pain disability index, and by increases in quality of life impairment by pain. (B) Improvement versus baseline in pain intensity index at end of observation.LMP: Lidocaine 700 mg medicated plaster; NRS: Numerical rating scale; OSM: Oral systemic medication; PIX: Pain intensity index; VAS: Visual analogue scale.

Table 4. Absolute change versus baseline in pain intensity index (primary effectiveness end point).

Figure 4. Patient Global Impression of Change after 24 weeks of treatment.

p < 0.001 in favor of lidocaine 700 mg medicated plaster.

Figure 4. Patient Global Impression of Change after 24 weeks of treatment.p < 0.001 in favor of lidocaine 700 mg medicated plaster.
Figure 5. Change in overall quality of life over the observation period (Short Form 12 questionnaire).

Boxplots show median (middle horizontal line in the box), 25 and 75% quartiles (bottom and top lines of the box), and five and 95% percentiles (whiskers).

BL: Baseline; MCS: Mental component score; PCS: Physical component score; W: Week.

Figure 5. Change in overall quality of life over the observation period (Short Form 12 questionnaire).Boxplots show median (middle horizontal line in the box), 25 and 75% quartiles (bottom and top lines of the box), and five and 95% percentiles (whiskers).BL: Baseline; MCS: Mental component score; PCS: Physical component score; W: Week.
Figure 6. Drug-related adverse events over the observation period.

DRAE: Drug-related adverse event; LMP: Lidocaine 700 mg medicated plaster; OSM: Oral systemic medication.

Figure 6. Drug-related adverse events over the observation period.DRAE: Drug-related adverse event; LMP: Lidocaine 700 mg medicated plaster; OSM: Oral systemic medication.

Table 5. All drug-related adverse events documented in patients receiving lidocaine 700 mg medicated plaster during the observation period (n = 1711).

Table 6. Main drug-related adverse events documented in patients receiving oral systemic first-line medication during the observation period (n = 1711).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.